Showing 1301-1310 of 1550 results for "".
- Analysis: Chronic Hand Eczema Affects 1 in 10 Adultshttps://practicaldermatology.com/news/chronic-hand-eczema-affects-1-in-10-adults-study-finds/2485383/A cross-sectional study of over 10,000 U.S. adults indicates chronic hand eczema (CHE) is more common than previously estimated, with nearly 1 in 10 reporting a physician diagnosis. The data, presented in a poster by Raj Chovati
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://practicaldermatology.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Small Case Series Shows Promise for Topical Roflumilast in HS Treatmenthttps://practicaldermatology.com/news/topical-roflumilast-shows-early-promise-for-mild-hs-in-case-series/2485022/A prospective case series published in JAAD Case Reports suggests that once-daily topical roflumilast 0.3% cream may be a promising off-label treatment for mild hidradenitis suppurativa (HS).
- NIH Grants for Vitiligo Research Rise Over Time, Driven by Medical Schools and NIAMShttps://practicaldermatology.com/news/nih-grants-for-vitiligo-research-rise-over-time-driven-by-medical-schools-and-niams/2484513/Funding trends National Institutes of Health (NIH) funding trends shows steady, long-term support for vitiligo research from 1985 through 2024, according to a new analysis. Using the NIH Research Portfolio Online Reporting To
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Case Study: Non-Invasive Combo Therapy Resolves Nodular BCChttps://practicaldermatology.com/news/case-study-non-invasive-combo-therapy-resolves-nodular-bcc/2476081/A combination of cryotherapy, 5-fluorouracil, and imiquimod achieved clinical resolution of a large nodular basal cell carcinoma (nBCC) in the inguinal region, according to a recent case report in the Journal of Clinical and Aest
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://practicaldermatology.com/news/prabotulinum-toxin-a-demonstrates-sustained-efficacy-at-day-180/2474898/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers publishing
- New LED Mask Targets Acne, Redness, Aging in One Sessionhttps://practicaldermatology.com/news/new-led-mask-targets-acne-redness-aging-in-one-session/2474546/Smuuv Body has introduced the Lulu Pro LED Mask in what it says is the first at-home device to deliver five clinically validated wavelengths in a single treatment. A press release from the manufacturer reported that the mask, d
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- Global Dermatology Lasers Market Projected to Hit $3.1B by 2029https://practicaldermatology.com/news/global-dermatology-lasers-market-projected-to-hit-31b-by-2029/2474203/The global dermatology lasers market is projected to grow from $2.27 billion in 2025 to $3.1 billion by 2029, according to a market report by The Business Research Company. This growth, according to a press release on the repo